抗血管內皮生長因子藥物Bevacizumab對抑制角膜新生血管之影響

Inhibitory Effect of Anti-VEGF Drugs Bevacizumab (Avastin) on Corneal Neovascularization

林念庭(Nien-Ting Lin)

指導教授 ： 林中天

共同指導教授 ： 陳偉勵

國立臺灣大學/生物資源暨農學院/獸醫學研究所/碩士(2008年)

https://doi.org/10.6342/NTU.2008.00391

摘要

正常眼角膜構造為透明無血管生長，當發生感染、炎症、乾眼症等角膜疾病時，眼角膜常會出現許多新生血管生成，過多的新生血管會導致炎症反應加劇，且導致眼角膜的透明度降低或喪失。血管內皮生長因子(vascular endothelium growth factor, VEGF) 在其中扮演了非常重要的角色，我們實驗以抗血管內皮生長因子(Anti-VEGF)藥物來拮抗血管內皮生長因子的作用進而阻斷角膜新生血管作用。實驗使用紐西蘭白兔進行體內試驗，我們以三種模式來建立角膜新生血管：角膜微晶格模式、角膜輪狀部幹細胞缺損模式及角膜化學灼傷模式。抗血管內皮生長因子藥物選擇Bevacizumab (Avastin

關鍵字

角膜 ； 新生血管 ； 血管內皮生長因子 ； 癌思停

並列摘要

The cornea is an avascular transparent structure normally. Corneal neovascularization may be initiated following infection, trauma, and inflammation, leading to decreased corneal transparency. Additionally, corneal neovascularization is a risk factor for graft rejection after allograft corneal transplantation. Vascular endothelium growth factor (VEGF) is known to have an important role in angiogenesis in the body. The anti-VEGF drugs have been proved to inhibit VEGF in previous reports on cancers and retina. In this study, we investigated the effects of anti-VEGF drug on corneal neovascularization in a rabbit model. Three models of corneal neovascularization in rabbits were used in this study, namely corneal micropocket, limbal stem cell insufficiency, and chemical burn. The anti-VEGF drug, bevacizumab (Avastin), was injected subconjunctivally for treating corneal neovascularization in these rabbit models. The maximal length and area of corneal neovascularization were measured and recorded. Histology analysis and immunochemical staining of the rabbit cornea were performed. Bevacizumab revealed inhibitory effect of corneal neovascularization in all of the three models. The treatment group showed lesser corneal neovascularization, inflammatory cells infiltration, and vascular endothelium cells by histology. Immunochemical stain revealed the expressions of the vascular endothelial cells and bevacizuzmab in cornea. In conclusion, subconjunctival injection of anti-VEGF drug, bevacizumab, can effectively suppress corneal neovascularization with no significant side effects based on this study. The dosage, administration routes, and efficacy in corneal diseases and allografts remains to investigate in the future.

並列關鍵字

cornea ； neovascularization ； vascular endothelium growth factor (VEGF) ； bevacizumab

參考文獻

1. Adamis AP, Shima DT. 2005. The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111-8.

2. Adamis AP, Meklir B, Joyce NC. 1991. In situ injury-induced release of basic-fibroblast growth factor from corneal epithelial cells. Am J Pathol. 139(5):961-7.

3. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 92(23):10457-61.

5. Andreoli CM, Miller JW. 2007. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 18:502-8.

6. Auerbach R, L:ewis R, Shinners B, Kubai L, Akhtar N. 2003. Angiogenesis assays: A critical overview. Clin Chem 49(1):32-40.